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Abstract: Selenium (Se) is an important trace element that should be present in the diet of all age
groups to provide an adequate intake. Se is incorporated in 25 known selenoproteins, which mediate
the biological effects of Se including, immune response regulation, maintenance of thyroid function,
antioxidant defense, and anti-inflammatory actions. A balanced intake of Se is critical to achieve
health benefits because depending on its status, Se has been found to play physiological roles or
contribute to the pathophysiology of various diseases including, neurodegenerative diseases, diabetes,
cancer, and cardiovascular disorders. Se status and intake are very important to be known for a
specific population as the levels of Se are highly variable among different populations and regions.
In the Middle East and North African (MENA) region, very little is known about the status of Se.
Studies available show that Se status is widely variable with some countries being deficient, some over
sufficient, and some sufficient. This variability was apparent even within the same country between
regions. In this review, we summarized the key roles of Se in health and disease and discussed the
available data on Se status and intake among countries of the MENA region.
Keywords: selenium; chronic diseases; Middle East; North Africa
1. Introduction
Selenium (Se) is a semi-solid metal that was discovered in 1817 as a byproduct of sulphuric acid
synthesis. It belongs to group 6 of the periodic table with an atomic number of 34. It is a red colored
powder; however, in vitreous form it is observed as black, and in crystalline form it is observed as
metallic gray. Se exists in many different oxidation states including 2+, 4+, 6+, and 2- [1]. Se is present
in small amounts in food mostly in organic forms (selenomethionine and selenocysteine) and rarely in
inorganic forms (selenate and selenite) [2]. Selenomethionine is usually derived from animal sources
in addition to cereal products grown in areas where the soil is rich in Se whereas selenocysteine is only
obtained from animal sources [3]. Inorganic forms are the major sources of Se incorporated into dietary
supplements [2]. Se concentrations in the soil where plants are grown or where animals are raised
are important indicators of Se intake in a country leading to tremendous variations among different
countries in Se status [2,4]. The most common sources of Se are Brazil nuts, cereals, offal, fish, eggs,
poultry, and vegetables [3–5].
Se is a necessary trace element that should be present in the diet of all age groups.
The Recommended Dietary Allowance (RDA) of Se is generally based on the optimum amount
that can maximize the activity of selenoprotein glutathione peroxidase [2–4]. This value was estimated
to be 55 µg/day for both males and females [2–4,6]. The Estimated Average Requirement (EAR) was
found to be around 45 µg/day for 19–50-year-old men and women and the tolerable upper intake level
(UL) is around 400 µg/day [3,4]. However, the optimal amount required to achieve maximum health
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benefits is unknown [3]. The World Health Organization (WHO) recommends that the optimum serum
concentration of Se for healthy adults is 39.5–194.5 ng/ml and that the concentration that maximizes
glutathione peroxidase activity is between 70 and 90 ng/ml [7,8].
Very limited data exist on Se toxicity in humans; however, animal studies are available on chronic
Se poisoning [4]. It was reported that an intake of around 800 µg/day of Se would cause no observed
adverse effect level (NOAEL), 1,540 to 1,600 µg/day of Se would result in low observed adverse effect
level (LOAEL) and 5,000 µg/day of Se is the toxic level where selenosis is expected to happen [3].
LOAEL is associated with symptoms of hair and nail brittleness and loss, garlic like breath odor,
gastrointestinal disturbances, and fatigue [3,4]. Selenosis can be associated with serious respiratory,
renal, and cardiac complications [3].
Se status can be assessed through blood, urine, nails, and hair levels. Blood specimens can be
either whole blood, erythrocytes, serum, or plasma. Erythrocytes, hair, and nails reflect long-term
status opposing to plasma or serum which reflect short-term levels. It is challenging to compare Se
levels across different countries due to the wide variations in methodologies of Se detection among
different laboratories [9,10].
2. Selenium: A Focus on Biology
2.1. Selenoproteins as Mediators of Se Actions
Se is an essential nutrient to human biology. The beneficial roles of Se to human health and
its requirement for life have been known for several decades. Se exists in 25 known selenoproteins,
some of which have important known biological functions [11]. The critical role of Se in human
health is particularly underscored by being the sole trace element specified in the genetic code
as selenocysteine, today recognized as the 21st amino acid, which has its proper genetic code,
specific biosynthesis pathway, and insertion mechanism. This amino acid exists in the active site
of many selenium-dependent enzymes that are responsible for multiple essential functions in the
human body [1,12,13]. In this case, Se acts as a redox center. For example, thioredoxin reductase,
a selenoenzyme, participates in DNA synthesis by reducing nucleotides which then helps in controlling
the redox state intracellularly [3]. Another example is iodothyronine deiodinases which activates
thyroid hormone [1]. Other selenoproteins have different functions including anti-inflammatory and
antioxidant effects; however, some of those functions are yet to be identified. The biological effects of
Se also include its participation in immune responses and thyroid function whereas its serum level can
also be linked with risk of diabetes, cardiovascular disease (CVD), and cancer [5]. Table 1 summarizes
the main functions and significance of the different known selenoproteins.
Table 1. Functions and significance of selenoproteins
Selenoprotein Symbol Function and Significance
Glutathione peroxidase 1 GPX1 Reduces cellular H2O2. Overexpression of GPX1 increasesrisk of diabetes.
Glutathione peroxidase 2 GPX2
Reduces peroxide in gut. GPX1/GPX2 double-knockout
mice develop intestinal cancer; one allele of GPX2 added
back confers protection.
Glutathione peroxidase 3 GPX3
Reduces peroxide in blood. Important for cardiovascular
protection, perhaps through modulation of nitric oxide
levels; antioxidant in thyroid gland.
Glutathione peroxidase 4 GPX4
Reduces phospholipid peroxide. Genetic deletion is
embryonic lethal; GPX4 acts as crucial antioxidant, and
sensor of oxidative stress and pro-apoptotic signals;
required for spermatozoa function.
Glutathione peroxidase 6 GPX6 Importance unknown.
Nutrients 2019, 11, 1457 3 of 13
Table 1. Cont.
Selenoprotein Symbol Function and Significance
Iodothyronine deiodinase 1 DIO1 Important for systemic active thyroid hormone levels.
Iodothyronine deiodinase 2 DIO2 Important for local active thyroid hormone levels.
Iodothyronine deiodinase 3 DIO3 Inactivates thyroid hormone.
Thioredoxin reductase 1 TXNRD1 Reduction of cytosolic thioredoxin. Genetic deletion isembryonic lethal.
Thioredoxin reductase 2 TXNRD2 Reduction of mitochondrial thioredoxin. Genetic deletionis embryonic lethal.
Thioredoxin-glutathione reductase TXNRD3 Reduction of thioredoxin, testes-specific expression.
Selenoprotein H SELENOH Involved in transcription. Essential for cell survival andantioxidant defense in Drosophila.
Selenoprotein I SELENOI Possibly involved in phospholipid biosynthesis.
Selenoprotein K SELENOK Involved in calcium flux in immune cells and endoplasmicreticulum (ER)-associated degradation.
Selenoprotein M SELENOM Thiol-disulfide oxidoreductase localized in the ER.Possibly involved in protein folding.
Selenoprotein F SELENOF Thiol-disulfide oxidoreductase localized in the ER.Possibly involved in protein folding.
Selenoprotein N SELENON Potential role in early muscle development. Mutationslead to multiminicore disease and other myopathies.
Selenoprotein O SELENOO Potential redox function, but importanceremains unknown.
Selenoprotein P SELENOP
Se transport to tissues particularly brain and testis. It also
functions as intracellular antioxidant in phagocytes.
Knockout leads to neurological problems and male sterility.
Methionine-R-sulfoxide reductase 1 MSRB1 Functions as a methionine sulfoxide reductase and MSRB1knockouts show mild damage to oxidative insult.
Selenoprotein S SELENOS Transmembrane protein found in plasma membrane andER. Reduces ER stress.
Selenoprotein T SELENOT ER protein involved in calcium mobilization.
Selenoprotein V SELENOV Testes-specific expression, potential role inmale reproduction.
Selenoprotein W SELENOW Potential antioxidant role, perhaps important inmuscle growth.
Selenophosphate synthetase 2 SEPHS2 Involved in the synthesis of all selenoproteins.
2.2. Synthesis and Co-Translational Incorporation of Selenocysteine in Humans
The cycle of selenocysteine synthesis and incorporation in humans begins with the attachment
of L-serine to non-cognate tRNASec by seryl-tRNA synthetase, an error that is not edited. This seryl
group gets phosphorylated by O-phosphoseryl-tRNASec kinase (PSTK) resulting in phosphoseryl
(Sep)-tRNASec intermediate. Finally, this Sep-tRNASec is converted into selenocysteinyl (Sec)-tRNASec
through O-phosphoseryl-tRNASec:selenocysteinyl-tRNASec synthase (SepSecS) in the presence of
selenophosphate and pyridoxal phosphate. Selenophosphate is the main Se donor in humans
synthesized from adenosine triphosphate (ATP) and selenide, the products of selenocysteine
degradation, by selenophosphate synthetase (SPS2). A specialized elongation factor (EFsec) then
delivers Sec-tRNASec to the ribosome. SElenoCysteine Insertion Sequence (SECIS), located in the
3′-UTR, helps localize EFsec and Sec-tRNASec near the translation site and forms a stem loop structure
which is necessary for decoding of selenocysteine UGA codon and its insertion into the nascent
protein [14–17]. The cycle of selenocysteine synthesis and incorporation into selenoproteins in humans
is summarized in Figure 1.
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deficiencies. Se deficiencies during pregnancy were also found to cause oxidative stress partly 
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an insulin mimetic when in the form of selenite. Moreover, several in vitro and in vivo studies have 
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3. Selenium in Health and Disease: The Importance of a Balanced Intake
Se depending on its status has been reported to play crucial roles in normal physiology or
contribute the pathophysiology of various diseases. Se has antioxidant and anti-inflammatory actions
and therefore various studies have assessed the impact of Se status on conditions characterized
by inflammation and oxida ive stre s including, neur degenerat ve diseases, diabetes, cancer, and
ardiovascular disorders [18].
3.1. Pregnancy
During pregnancy, the demand for multiple nutrients increase owing to many physiological
changes, resulting in deficiencies of many vitamins and minerals [9,19]. Those deficiencies might
sometimes lead to complications to the fetus or to the mother. Se levels were found to be significantly
reduced during pregnancy [9,19]. During the first trimester, GPx activity was found to be reduced
significantly and this low level was aintained throughout the second and third trimesters with
a slight increase during delivery [20]. Subsequently, in the second and third trimesters, Se levels
were noted to be significantly reduced with further reduction during delivery [20]. Due to this
increased demand, the RDA for Se during pregnancy was increased from 55 µg/day to 60 µg/day [19,21].
Se deficiencies in pregnant women might have adverse effects on the developing fetus, particularly
the nervous system. A case-control study of pregnant women found a positive correlation between
low Se levels and the occurre ce of neural tube defects [22]. However, it is important to note that
efects in the nervous syste development are affected by multiple other factors and not solely by
Se deficiencies. Se deficie cies d ring pregnancy ere als found to cause oxidative stress partly
resulting i miscarriages, pre-term deliveries, intrauterine growth retardations, preeclampsia, thyroid
dysfunctions, gestational diabetes, a d cholestasis [9,23]. Therefore, it is important to maintain optimal
Se levels during pregna cy by increasing Se intake to meet the i creased demand.
3.2. Diabetes Mellitus
The relationship between Se and diabetes was inve tigated in mul iple studi s with contradicting
results [18]. Those studies were conducted initially following the assumption that Se is likely to exert
protective effects against diabetes due to its antioxidant actions. In support of this assumption, Se was
found to delay the onset and progression of diabetes. Se was also found to act as an insulin mimetic
when in the form of selenite. Moreover, several in vitro and in vivo studies have suggested that Se
plays an important role in the regulation of glucose homeostasis [18,24]. Human studies have also
investigated the impact of Se on diabetes yet with conflicting conclusions. Both low and high levels
of Se have been shown to be associated with a risk of diabetes [2]. The role of Se in diabetes was
assessed in few randomized control trials (RCT). The first large RCT was the Nutritional Prevention
of Cancer (NPC) trial which aimed at assessing the effect of 200 µg of daily Se supplementation on
reducing the risk of skin cancer compared to placebo [25]. A secondary analysis of the data after a
follow-up of 7 years suggested a statistically significant increase in the incidence of type 2 diabetes
among those who received Se supplementation compared to placebo [26]. In contrast, the Se and
Vitamin E Cancer Prevention Trial (SELECT) found no statistically significant increase in the incidence
of type 2 diabetes after Se supplementation [27]. The third trial is the Se and Celecoxib (Sel/Cel) Trial.
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The intervention was a randomized, placebo controlled trial of Se (200 µg/day) and cyclooxygenase 2
selective inhibitor, celecoxib (400 mg, once per day), alone or in combination, for the prevention of
colorectal adenoma in men and women. After exclusion of participants who had type 2 diabetes prior
to the trial, 1640 participants were assessed for the presence of type 2 diabetes during the follow-up
period. Authors found that 31 participants randomized to Se and 25 randomly assigned placebo were
diagnosed with type 2 diabetes; however, despite a higher number of cases in the Se arm, the difference
was not statistically significant. Interestingly, the study showed a statistically significant increase in the
risk of type 2 diabetes in elderly individuals, which suggests that with old age supplementation with
Se may increase the risk of type 2 diabetes [28]. These findings mirror the controversy on whether
higher Se concentrations could increase the risk of type 2 diabetes or not.
Observational studies have also shown a non-linear association between Se and type 2 diabetes.
A recent, comprehensive meta-analysis that was conducted in 2019 among 20 observational studies
concluded that high Se levels are significantly associated with type 2 diabetes (pooled odds ratios, 1.88;
95% confidence interval, 1.44 to 2.45). However, significant heterogeneity was observed within different
studies and the analysis of the funnel plot revealed significant publication bias. Subgroup analysis was
also conducted according to the method of Se measurement in each study. Significant association was
shown among studies that used blood, diet, and urine as specimens for Se level detection but not in
studies that used nails as a sample for Se measurement. Sensitivity analysis was conducted in addition
to the trim and fill analysis to account for the heterogeneity and the publication bias, yet the results
were consistent upon all adjustments [18]. Another non-linear dose–response analysis confirmed that
both levels below and above the physiological range are potential risk factors for diabetes which is
consistent with other review articles that suggested a U-shaped relationship between Se and diabetes.
Positive associations were detected among patients with low Se levels (<100 µg/l) and patients with
high Se levels (>130 µg/l) [29].
3.3. Cardiovascular Disease (CVD)
Se as an antioxidant was assumed to play an essential role in protecting against atherosclerotic
events and CVD [30]. Se deficiency was directly linked to Keshan disease, an endemic cardiomyopathy
that is found in regions where Se intake is very low [31]. Multiple studies were carried out to assess
the impact of Se on CVD risk. Both low and high levels of Se were found to adversely affect heart
function [2]. In Eastern USA, a post hoc analysis of the NPC trial was conducted with a follow-up
of 7.6 years to study the effect of Se supplementation on the prevention of CVD. The incidence of
myocardial infarction, total cerebrovascular accidents and CVD were assessed, and the results revealed
that there is no overall benefit of supplementing 200 µg/day of Se to prevent CVD [26]. The SELECT
trial did not also find any significant effect of Se on overall cardiovascular events [27]. A meta-analysis
of RCTs showed that oral Se did not have an overall effect on cardiovascular events regardless of Se
formulation or dose [32]. Observational studies have shown conflicting conclusions. A meta-analysis
of observational studies concluded a nonlinear, U-shaped relationship, between Se levels and CVD
risk. The suggested range of Se concentrations that results in significant beneficial effects against CVD
is from 55 to 145 µg/l [32].
3.4. Cancer
The role of Se in cancer prevention was extensively studied in various cancer types. Se exerts its
action through the antioxidant activity of selenoproteins in addition to several other mechanisms [33].
However, some laboratory studies suggested that Se can promote malignant cell transformation and
progression [34]. Therefore, whether Se promotes or prevents cancer is not fully clear. Various RCTs
investigated Se supplementation for cancer prevention. The first RCT is the NPC trial that aimed
at assessing the influence of Se on the development of non-melanoma skin cancer. The NPC trial
concluded that Se does not exert a chemoprotective effect against the recurrence of non-melanoma
skin cancer, yet it significantly reduced the risk for all cancers, and for esophageal, prostate, colorectal,
Nutrients 2019, 11, 1457 6 of 13
and lung cancers [25]. Another smaller trial among patients who received organ transplants found
an unexpected increase in the incidence of non-melanoma skin cancer as a secondary outcome in
Se-supplemented group [35]. The SELECT trial was a pivotal study that was carried out in male
general population without high risk of prostate cancer to assess the incidence of prostate cancer among
Se-supplemented participants compared to placebo. The study found no significant difference in
prostate cancer incidence between Se-supplemented and placebo groups. It also detected no difference
in overall cancer risk or any other cancer types [27]. Moreover, three recent RCTs evaluated Se impact
on participants with high risk for prostate cancer and all showed no beneficial effect of Se on the
incidence of cancer [36–38]. Additionally, a trial among women with high risk of breast cancer due to
mutations to breast cancer type 1 (BRCA1) susceptibility gene showed increased risk of all cancers
and primary breast cancer in Se-supplemented arm compared to placebo [39]. Observational studies
have also assessed Se effect on cancer risk with strongly conflicting results. A recent meta-analysis
of observational cohort studies showed an overall lower risk of cancer among participants with the
highest baseline exposure levels, yet the included studies are subject to a substantial risk of bias [40].
4. Regional Variability of Se Status: A Focus on the Situation in the Middle Eastern and North
Africa (MENA) Region
The status of Se across the MENA region is widely variable with some countries deficient,
some over sufficient and some sufficient in addition to several countries with unknown Se status.
This variability was apparent even between provinces from the same country. These tremendous
variations may be linked to the varying concentration of Se in the soil were food consumed is gown.
We summarized in this review the available evidence on Se status and intake among countries of
the MENA region. It is important to note that most of the studies that assessed Se concentrations in
biological samples were case-control studies with small sample sizes that cannot be generalized to the
whole population. Few studies addressed Se status in a small number of countries with total paucity
of information in many other countries of the MENA region. Available evidence on Se status among
countries of the MENA region are summarized in Figure 2.
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4.1. Turkey
A study that analyzed Se concentrations in colostrum, transitional and mature breast milk
among healthy lactating women concluded that Se content is below the international reference
range set at 18.5 µg/l among all different samples throughout the lactation period [41]. Moreover,
analysis was extended to dairy milk products in Turkey collected from different cities and its findings
revealed that goat milk had the highest content followed by sheep milk and finally cow milk had
the lowest Se content [41]. A more recent study included all dairy products in the analysis and
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found that concentrations varied based on the type of food with butter and cheese having higher
concentrations; however, other products such as ice cream, milk, and yogurt had almost no Se
content [42]. The estimated daily intake of Se among children was reported as 30-40 µg/day [43].
However, with regards to Se concentrations in blood, multiple case-control studies were conducted
among different healthy and patient populations including infants, children, adults, pregnant women,
and postmenopausal women. Other studies also used samples from erythrocytes and semen to assess
Se concentrations [44,45]. Overall, values were widely variable ranging from 50–138 µg/l in healthy
populations [43–55].
4.2. Jordan
A survey of groundwater was conducted to assess the levels of Se in multiple aquifers in Amman
Zarqa Basin. Se levels were various among different aquifers ranging from 0.09 to 742 µg/l with an
average of 24 µg/l, which exceeds WHO recommended threshold for drinking water [56]. A later
case-control study of colorectal cancer patients assessed the dietary intake of Se which was found to
be 59.26 ± 8.91 µg/day for controls. This value is higher than the RDA (55–70 µg/day) [57]. On the
other hand, Se concentrations were analyzed in two studies using blood and hair samples [58,59].
Blood concentrations in non-smokers were found to be around 187 µg/l which is relatively high [58].
4.3. Iran
Multiple studies were conducted in Iran among various populations, children, adults, and
elderly [60–62]. Se intake was found to be adequate in children and adults [60,61], whereas in
postmenopausal women, Se intake was significantly lower than the RDA (55 µg/day) [62]. Se levels in
rice samples from Iran were assessed and they were found to be relatively high [63]. Se status in Iran
was assessed in various studies in healthy and patient populations. Blood concentrations ranged from
58–123 µg/l in children, adults and pregnant women [64–77].
4.4. Kingdom of Saudi Arabia (KSA)
A study was conducted to assess the content of Se in wheat grains grown in KSA. This study
reported highly variable concentrations ranging from 8 to 293 µg/kg [78]. Other recent studies that
quantified the intake of Se estimated the intake to be 75–121.65 µg/day and 93 µg/day in the regions
of Jeddah and Riyadh, respectively [79,80]. Moreover, surveys of infant milk formulas, breast milk
and cow’s milk were conducted to determine Se intake in infant/children populations. The findings
of those surveys showed that infant milk formulas contained adequate amounts of Se whereas some
breast-fed infants might have lower than recommended Se intakes [81,82]. On the other hand, Se
status was assessed in multiple case-control studies in KSA. Those studies were done using various
samples; serum, urine, toenails, whole blood, umbilical cord blood, and placental tissue [5,80,83–91].
Blood concentrations varied widely from as low as 32 µg/l to 195 µg/l [5,80,85–88,90,91].
4.5. Egypt
Se intake among healthy children in Egypt was found to be 8.3 ± 2.3 mg/day [92]. Case-control
studies in Egypt were mainly done on children, and reported Se concentrations ranging from
65–83 µg/l [93–95]. Studies have also assessed Se concentrations in neonates and their mothers and the
concentrations were found to be 86 µg/l and 118 µg/l, respectively [96].
4.6. Qatar
In Qatar, no direct studies were conducted to assess the intake of Se among Qatari population.
However, according to Qatar General Electricity & Water Corporation (Kahramaa) drinking water
quality requirements report, Se is not expected to be present in Qatar’s water system [97]. This indicates
that the Qatari population is not expected to have any Se intake from drinking water sources.
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Additionally, a market basket survey of Se in rice imports in Qatar, the primary staple dish, concluded
that for Qatari citizens, rice compensates for more than 100% of RNI Se (30 µg/day) regardless of the
gender or the type of rice consumed. However, for non-Qatari expatriates (over 80% of the population),
with a much lower rice consumption, the percentages were variable according to gender and type of
rice consumed, yet they were all below 100% of RNI Se [98]. Further analysis included rice-based
infant cereals in Qatar which was found to provide around 63% of RNI Se based on the recommended
daily serving [98]. This can conclude that rice consumption in Qatar is a significant contributor to the
daily intake of Se. However, Se status in Qatar was not assessed in any of the few studies available.
5. Conclusions
Se plays a very important role in health and hence Se status and intake are very important to be
known for a specific population as the levels of Se are highly variable among different populations and
regions. Studies conducted in the MENA region to assess Se status and intake are very limited and most
of those available were designed as case-control protocols with small sample sizes. For those countries
with data available such as Iran, Turkey, and KSA, more powered, rigorous, and well-designed studies
should be conducted to assess Se status among different populations in that specific country or regions
that share more or less similar lifestyle and climate such as the six countries of the Gulf Cooperation
Council (GCC). Se intake should also be assessed using food surveys and through surveying Se content
in staple food (e.g., rice) especially that most of food products consumed in a large number of countries
of the MENA region are imported from various parts of the world which may have variable Se
content in the soil. Moreover, for many countries within the MENA region, including Qatar and most
North-African countries, data about Se status is totally absent. This warrants the need for rigorous and
well-constructed studies to determine Se intake and status among the general population and specific
populations, such as children and pregnant women, in those countries. Furthermore, studying the
relationship between Se status and the incidence of chronic diseases, such as diabetes and CVD in the
MENA region would help in devising novel preventive approaches for these disorders particularly
prevalent in many countries of this region.
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